Analysis by Profiling Technology (Omics Technologies, Imaging Technologies, and Immunoassays); by Biomolecule (Genetic, Protein and Glyco Biomarkers); by Cancer Type (Breast, Lung, Prostate, Colorectal, Stomach, and Other Cancers); and by Application (Diagnostics, Drug Discovery & Development Prognosis, Risk Assessment, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033
Buy Now
The global cancer biomarkers market is estimated to garner a revenue of ~USD 33 Billion by the end of 2033 by growing at a CAGR of ~14% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 13 Billion in the year 2022. The growth of the market can be attributed to the growing patient base of various types of cancers comprising lung, prostate, breast, colorectal, ovarian cancer, and so on throughout the world. For instance, the number of new cancer cases in 2018 in the U.S. was 1,752,735 with the death of 599,589 people. Further, the rising consumer awareness regarding cancer biomarkers, coupled with the radically expanding use of cancer biomarkers for novel drug discovery, is estimated to hike the market growth during the coming years.
Get more information on this report:Download Sample PDF
In addition to these, factors that are believed to fuel the market growth of cancer biomarkers include the worldwide rise in the geriatric population who are more vulnerable to fatal diseases such as cancer. Therefore, these individuals need the best possible care and prompt treatment for these conditions. According to the World Health Organization (WHO) estimations, the global population of individuals aged 60 and above is predicted to rise from 1 billion in 2020 to 1.4 billion by 2030. The world's population of individuals aged 60 and above is expected to double to 2.1 billion by 2050. Additionally, the growing proportion of research and development activities on cancer biomarkers, coupled with the increasing number of clinical research organizations across the world is expected to propel the growth of the cancer biomarkers market size during the forecast period. For instance, the number of clinical research organizations in 2022 across the world was nearly 3000 with a 0.3% rise from 2021.
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~14% |
|
Base Year Market Size (2022) |
~ USD 13 Billion |
|
Forecast Year Market Size (2033) |
~ USD 33 Billion |
|
Regional Scope |
|
Growth Drivers
Growing Prevalence of Cancer – Cancer prevalence is defined by how often cancer occurs (incidence rate) and how long a person lives with it after diagnosis (survival rate). Thus, the most common cancer with the longest survival rate will have a high prevalence value. For instance, breast cancer in women and prostate cancer in men had high prevalence rates with 42% and 43% in 2019, as per estimations throughout the world.
Elevating R & D Activities and Investments – For instance, the global cancer research and development activities continued to surge in 2021 with an increase of 50% more trail starts from 2021.
Increasing Biotechnology and Pharmaceutical Companies – Between 2017 to 2018, about 46 new molecular entities and 59 biologic license applications were approved by the U.S Food and Drugs Administration, and in 2019, out of the 59 newly approved drugs, 19 were first-in-class drugs. Also, the contracts worth for biotech and pharmaceutical companies are estimated to reach USD 150 billion before the first quarter of 2019 in the U.S.
Rising Use of Biomarkers in the Medical Sector – As per the observations, more than 50% of clinical trials used biomarkers in 2018, up from over 10% use in 2000 across the globe.
Increasing New Drug Developments – Based on a drug development report, FDA-approved biomarkers such as activating mutations in epithelial growth factor receptors (EGFR) can predict the efficiency of EGFR inhibitors, such as gefitinib, a targeted cancer drug. The response rate for gefitinib was more than 60% in selected patients and about 25% in unselected patients.
Challenges
The global cancer biomarkers market is segmented and analyzed for demand and supply by cancer type into breast, lung, prostate, colorectal, stomach, and other Cancers. Out of these segments, the breast cancer segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the rising prevalence of breast cancer on account of unhealthy lifestyles, genetic inheritance, the rising female geriatric population, and exposure to hazardous radiation. As per the World Health Organization, in 2020, about 2.3 billion women are diagnosed with breast cancer, and 685,000 people died across the world.
The global cancer biomarkers market is also segmented and analyzed for demand and supply by profiling technology into omics technologies, imaging technologies, and immunoassays. Amongst these three segments, the omics technologies segment is expected to garner a significant share. The growth of the segment can be attributed to the high efficiency of omics technologies in the diagnosis of cancer, along with the increasing development of profiling techniques for cancer biomarkers, that is anticipated to boost the market’s growth during the forecast period.
Our in-depth analysis of the global cancer biomarkers market includes the following segments:
|
By profiling Technology |
|
|
By Biomolecule |
|
|
By Cancer Type |
|
|
By Application |
|
The North America cancer biomarkers market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed majorly to the rising population count & growing research activities, followed by the surging ratio of health insurance covering various cancer biomarker diagnoses. Furthermore, the rise in personal income and affordability of advanced treatments among people is estimated to fuel the market growth during the forecast period. As per the U.S Bureau of Economic Analysis, the personal income of people in the U.S. rose to USD 71.6 billion at the rate of 0.3% per month, and consumer spending rose to USD 67.5 billion at the rate of 0.4% in August 2022. Further, the rising adoption of cancer biomarkers, along with the proliferation of research and development of novel products to treat cancer are further factors that are estimated to spur market growth in the coming years. In addition, increasing adoption ratio of next-generation sequencing are also anticipated to boost the market growth during the forecast period.
Furthermore, the Asia Pacific cancer biomarkers market is projected to display notable growth over the forecast period on the back of the accelerating prevalence of cancer in nations such as Japan, and China. For instance, more than 5 million new cancer cases were reported in China in 2020. With almost 850,000 new cases, lung cancer was the most prevalent type of cancer. Moreover, the surge in disposable income, growth in the geriatric population, and increasing investment in the research and development of biomarkers in the form of digital biomarker are some further factors that are projected to expand the global cancer biomarkers market size during the projected timeframe in the region.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: Growing prevalence of cancer, elevating R & D activities and investments, rising use of biomarkers in the medical sector are the major factors driving the market growth.
Ans: The market is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023 – 2033.
Ans: The dearth of reimbursement policies for biomarker testing, and requirement of hefty capital investment for research and development activities are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
Ans: The major players in the market are INOVIQ, Bio-Rad Laboratories, Inc., Abbott Laboratories, Becton, Dickinson and Company, Merck KGaA, CENTOGENE GmbH, PerkinElmer Inc., Siemens Healthcare GmbH, and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by profiling technology, biomolecule, cancer type, application, and by region.
Ans: The breast cancer segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
